These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31521479)

  • 21. Accepting hepatitis C virus-infected donor hearts for transplantation: Multistep consent, unrealized opportunity, and the Stanford experience.
    Moayedi Y; Gulamhusein AF; Ross HJ; Teuteberg JJ; Khush KK
    Clin Transplant; 2018 Jul; 32(7):e13308. PubMed ID: 29869354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heart Transplant Using Hepatitis C-Seropositive and Viremic Organs in Seronegative Recipients.
    Zhu Y; Shudo Y; Lee R; Woo YJ
    Ann Transplant; 2020 Jun; 25():e922723. PubMed ID: 32527989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heart Transplantation for Hepatitis C Virus Non-Viremic Recipients From Hepatitis C Virus Viremic Donors.
    Frager SZ; Dhand A; Gass A; Levine A; Spielvogel D; Nog R; Wolf DC; Bodin RI
    Cardiol Rev; 2019; 27(4):179-181. PubMed ID: 31180937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of Kidney Transplants from Viremic and Non-Viremic Hepatitis C Virus Positive Donors into Negative Recipients: Results of the Spanish Registry.
    Franco A; Moreso F; Solà-Porta E; Beneyto I; Esforzado N; Gonzalez-Roncero F; Sancho A; Melilli E; Ruiz JC; Galeano C;
    J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of HCV Ab+/NAT- donors in HCV naïve renal transplant recipients to expand the kidney donor pool.
    Dao A; Cuffy M; Kaiser TE; Loethen A; Cafardi J; Luckett K; Rike AH; Cardi M; Alloway RR; Govil A; Diwan T; Sherman KE; Shah SA; Woodle ES
    Clin Transplant; 2019 Jul; 33(7):e13598. PubMed ID: 31104346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased early acute cellular rejection events in hepatitis C-positive heart transplantation.
    Gidea CG; Narula N; Reyentovich A; Fargnoli A; Smith D; Pavone J; Lewis T; Karpe H; Stachel M; Rao S; Moreira A; Saraon T; Raimann J; Kon Z; Moazami N
    J Heart Lung Transplant; 2020 Nov; 39(11):1199-1207. PubMed ID: 32739334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys.
    Potluri VS; Goldberg DS; Mohan S; Bloom RD; Sawinski D; Abt PL; Blumberg EA; Parikh CR; Sharpe J; Reddy KR; Molnar MZ; Sise M; Reese PP
    J Am Soc Nephrol; 2019 Oct; 30(10):1939-1951. PubMed ID: 31515244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of heart transplantation using hepatitis c-viremic donors: A systematic review with meta-analysis.
    Villegas-Galaviz J; Anderson E; Guglin M
    J Heart Lung Transplant; 2022 Apr; 41(4):538-549. PubMed ID: 35153130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing Tissue Transmission of Hepatitis C Virus From Viremic Donor to Seronegative Kidney Transplant Recipients: A Case Series.
    Franco A; Gosalvez C; Gimeno A; Trigueros M; Balibrea N; Perez Contreras FJ
    Transpl Int; 2023; 36():11110. PubMed ID: 37534060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study.
    Crismale JF; Khalid M; Bhansali A; De Boccardo G; Khaim R; Florman SS; Shapiro R; Schiano TD
    Clin Transplant; 2020 Jan; 34(1):e13761. PubMed ID: 31808193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Access to direct-acting antivirals for hepatitis C-negative transplant recipients receiving organs from hepatitis C-viremic donors.
    Bova S; Cameron A; Durand C; Katzianer J; LeGrand M; Boyer L; Glorioso J; Toman LP
    Am J Health Syst Pharm; 2022 Jan; 79(3):173-178. PubMed ID: 33987658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac allograft vasculopathy in heart transplant recipients from hepatitis C viremic donors.
    Kadosh BS; Birs AS; Flattery E; Stachel M; Hong KN; Xia Y; Gidea C; Aslam S; Razzouk L; Saraon T; Goldberg R; Rao S; Pretorius V; Moazami N; Smith DE; Adler ED; Reyentovich A
    Clin Transplant; 2024 Apr; 38(4):e15294. PubMed ID: 38545881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals.
    La Hoz RM; Sandıkçı B; Ariyamuthu VK; Tanriover B
    Am J Transplant; 2019 Nov; 19(11):3058-3070. PubMed ID: 31207073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
    Eckman MH; Woodle ES; Thakar CV; Alloway RR; Sherman KE
    Am J Kidney Dis; 2020 Jun; 75(6):857-867. PubMed ID: 32081494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of severe BK viremia in a patient receiving a kidney transplant from a hepatitis C virus-positive donor: A case report.
    Gray M; Borges L; Conrath M; Marti K
    Am J Health Syst Pharm; 2024 Jan; 81(2):56-60. PubMed ID: 37793014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C.
    Schlendorf KH; Zalawadiya S; Shah AS; Perri R; Wigger M; Brinkley DM; Danter MR; Menachem JN; Punnoose LR; Balsara K; Sacks SB; Ooi H; Awad JA; Sandhaus E; Schwartz C; O'Dell H; Carver AB; Edmonds CL; Ruzevich-Scholl S; Lindenfeld J
    JAMA Cardiol; 2020 Feb; 5(2):167-174. PubMed ID: 31851352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation.
    Sise ME; Strohbehn IA; Chute DF; Gustafson J; Van Deerlin VM; Smith JR; Gentile C; Wojciechowski D; Williams WW; Elias N; Chung RT
    Kidney Int Rep; 2020 Apr; 5(4):459-467. PubMed ID: 32280841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of hepatitis C viremic donor lung allograft characteristics on post-transplantation outcomes.
    Woolley AE; Piechura LM; Goldberg HJ; Singh SK; Coppolino A; Baden LR; Mallidi HR
    Ann Cardiothorac Surg; 2020 Jan; 9(1):42-48. PubMed ID: 32175238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse.
    Gottlieb RL; Sam T; Wada SY; Trotter JF; Asrani SK; Lima B; Joseph SM; Gonzalez-Stawinski GV; Hall SA
    J Card Fail; 2017 Oct; 23(10):765-767. PubMed ID: 28801074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up of acute and chronic rejection in heart transplant recipients from hepatitis C viremic (NAT+) donors.
    Stachel MW; Alimi M; Narula N; Flattery EE; Xia Y; Ramachandran A; Saraon T; Smith D; Reyentovich A; Goldberg R; Kadosh BS; Razzouk L; Katz S; Moazami N; Gidea CG
    Am J Transplant; 2022 Dec; 22(12):2951-2960. PubMed ID: 36053676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.